Aurora, Colorado 80045


Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.

Study summary:

STUDY DESIGN Many patients undergo thyroidectomy for nodular thyroid disease. They have normal thyroid function prior to surgery and are immediately placed on standard thyroid hormone replacement therapy (levothyroxine, LT4) after surgery. The levothyroxine dose is titrated every 6-8 weeks to normalize the thyroid stimulating hormone (TSH) level. The investigators aim to study this population before surgery when the patients still have endogenous thyroid function and after surgery once their TSH has been normalized to pre-surgery levels. Using a weight based dosing strategy (1.6mcg/kg), most patients will remain euthyroid throughout this process. This experimental design eliminates many of the confounding variables that have plagued previous thyroid replacement trials. One of the most difficult aspects of conducting these types of studies is testing a uniform patient population. The most common cause of hypothyroidism is autoimmune thyroiditis (Hashimoto's thyroiditis) and previous studies have largely focused on these patients. The difficulty in testing patients with autoimmune thyroid failure is that even though they have a common illness, the disease course is extremely variable. Each patient may have different degrees of thyroid failure and may still be making different amounts of endogenous thyroid hormone. The presence of thyroid autoantibodies has also been reported to have systemic effects, and may influence perception of overall health and sense of well-being. This study will focus on a more homogenous population without the potential cofounders inherent to patients with autoimmune thyroid disease. Each patient will serve as their own control and also avoid any cognitive or somatic effects that temporary hypothyroidism may induce. No study has ever evaluated a patient's symptoms before and after replacement with thyroid hormone when the patient is euthyroid before thyroid hormone therapy. The assumption has been made that if serum TSH is normalized, thyroid hormone levels are adequate and that symptoms of hypothyroidism have been relieved. The investigators know from large community based studies that symptoms of hypothyroidism persist despite what the investigators believe is "adequate" thyroid hormone replacement in as many as 10% of patients. Our study will be the first to test the same patient, before and after thyroidectomy so the investigators can directly compare normal endogenous thyroid function with levothyroxine (LT4) therapy resulting in the same serum TSH. Thyroidectomies are often performed for large nodules or nodules that show indeterminate or suspicious cytology after fine needle aspiration biopsy, but turn out to be benign at final histological diagnosis. The current standard of care is to replace thyroid hormone with LT4 to normalize the serum TSH. Our approach uses the same patient as their own control and eliminates numerous variables that cannot be controlled for in other studies including: variable onset of hypothyroidism, degree of endogenous thyroid function and underlying cause of hypothyroidism. Prior to and after surgery, the investigators will measure each patient's thyroid levels (TSH, free T4, total T4, total T3, thyroxine binding globulin, sex hormone binding globulin, lipid panel, and iron), and parathyroid/calcium function (parathyroid hormone, calcium, albumin, vitamin D25), and deiodinase type 2 polymorphism status will be determined on pre-surgery bloodwork. Thyronamine levels will also be measured before and after surgery. Thyronamines are thyronergic metabolites of thyroid hormones that can decrease metabolism and induce behavioral inactivity in mouse models. A recently developed sensitive chemiluminescent antibody assay for 3-Iodothyronamine has been developed and patients on levothyroxine therapy after thyroidectomy had higher thyronamine levels compared with euthyroid controls. Based on these studies, the investigators hypothesize, as a secondary measure that patients with a higher thyronamine level after surgery, or greater pre- vs post-surgery thyronamine level will have worse outcomes, defined by the questionnaires. Patients will complete a series of questionnaires (SF-36 measure of overall health, Billewicz measure of thyroid health, HADS measure of anxiety and depression) as well as undergo working memory testing using the N-back and cognitive function testing using the Sustained Attention to Response Test (SART). Lab analysis will also be performed before surgery to look at targets of thyroid hormone action including low density lipoprotein (LDL) cholesterol and sex hormone binding globulin (SHBG). Following surgery, only patients benign results or low-risk differentiated thyroid cancer not requiring radioiodine therapy or TSH suppression will continue on the study. The patients continuing in the study will have their dose of levothyroxine titrated with the goal of matching their pre-surgery TSH +/- 1 milli-international units per liter (mIU/L). 6 months following surgery, lab testing, questionnaires and cognitive testing will be repeated. Timing the second set of testing 6 months will allow adequate time to match the post-surgery TSH to the pre-surgery level and give adequate time for any cognitive effects resulting from the surgery itself to dissipate. The primary endpoint will compare changes in scores on the N-back test before and after surgery from those in the deiodinase CC polymorphism group to those in the deiodinase type 2 TC and TT groups. Secondary endpoints will include scores on the SART and well-being questionnaires before and after surgery to correlate with deiodinase polymorphisms as well as correlation of these outcome measures with serum thyronamine levels before and after surgery as an exploratory measure. An optional sub-study is being made available to research subjects to compare the stool microbiota longitudinally, with the initial stool sample at the start of the study in the presence of normal systemic thyroid hormone levels and then again after thyroidectomy while taking oral levothyroxine. Comparisons of any microbiota compositional changes from before and after surgery will be made to any changes in symptoms, cognition/memory testing and overall quality of life. Any exposure to antibiotics, probiotics or other updates to medical history will be documented at each visit. Any exposure to systemic antibiotics in the previous 60 days of the first study collection or between collections will be excluded. Subjects will complete a 3-day lead-in dietary log prior to each stool collection, summarizing meal compositions on 3 consecutive days before the stool sample is collected and submitted. Participants will be given their own dietary log again and encouraged to follow a similar diet prior to the second stool collection.


Inclusion Criteria: - TSH in the ideal reference range (0.4-4.0 milli-international units per liter (mIU/L)) - Planned thyroidectomy for nodular thyroid disease or low-risk differentiated thyroid cancer (<4cm, no ETE, no expected use of RAI or suppressive levothyroxine therapy) Exclusion Criteria: - History of psychiatric illness (major illness as defined by DSM IV: major depression, schizophrenia, mania, etc). Patients prescribed chronic medications for psychiatric illness, those taking benzodiazepines or anti-seizure medication. - Estrogen therapy that is new within the last 6 weeks or if the dose has been changed within the last 6 weeks - Positive thyroid antibodies - Chronic use (>4 weeks) of concomitant medications that could affect cognition and memory (including sedative hypnotics, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, Topamax, benzodiazepines, etc.) - Pregnancy - Steroid therapy - Persistent cancer of any type or other major medical illness



Primary Contact:

Principal Investigator
Bryan R Haugen, M.D.
University of Colorado Denver Anschutz Medical Campus

Emma Hulseberg-Dwyer
Phone: 720-848-5146

Backup Contact:

Kelsi Deaver, M.D.
Phone: 720-848-2650

Location Contact:

Aurora, Colorado 80045
United States

Emma Hulseberg-Dwyer
Phone: 720-848-5146

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.